DO YOU HAVE THESE SYMPTOMS
DO YOU HAVE THESE SYMPTOMS
HIGH STRENGTH FORMULA FOR ALL VISION CONCERNS
Combining the most clinically researched ingredients for best vision support, Diamond Vision PRO, Ultimate Vision 4X and Ultimate Vision PRO 4X is the first eye supplement to be enhanced with a proprietary 4X technology.

FloraGLO® Lutein 4X delivers 4 times higher absorption than conventional FloraGLO® Lutein. This also means that is is more potent and offers even better results than typical eye supplements.

HIGH STRENGTH FORMULA FOR ALL VISION CONCERNS

Combining the most clinically researched ingredients for best vision support, Diamond Vision PRO, Ultimate Vision 4x and Ultimate Vision PRO 4X is the first eye supplement to be enhanced with a proprietary 4X technology.

FloraGLO® Lutein 4X delivers 4 times higher absorption than conventional FloraGLO® Lutein. This also means that is is more potent and offers even better results than typical eye supplements.

The Macular is The Focal Point to Good Vision

The macular is a small area in the centre of the retina at the back of the eye that is responsible for sharp, clear central vision and the ability to perceive colour. A healthy macular pigment should be rich in lutein and zeaxanthin.
Both lutein and zeaxanthin are responsible for absorbing harmful blue light, thereby acting as a filter to protect the macular.
The Macular is The Focal Point to Good Vision

The macular is a small area in the centre of the retina at the back of the eye that is responsible for sharp, clear central vision and the ability to perceive colour. A healthy macular pigment should be rich in lutein and zeaxanthin.

Choose the Most Clinically Researched Lutein
Research has shown that low macular pigment optical density (MPOD) is a key risk of age-related macular degeneration (AMD). Supplementary lutein can help increase MPOD, but for maximum efficacy highest absorbability, choose FloraGLO® Lutein 4X.

MPOD, mean difference (4mo – 0 mo)BaselineTemporal Retinal Eccentricity(°)(Am J Clin Nutr 87(5): 1521-1529 (2008)))

